DMD Patient

CONSIDER EMFLAZA AS A FOUNDATIONAL TREATMENT FOR SLOWING THE PROGRESSION OF DUCHENNE

Evidence from clinical trials demonstrates that when compared to placebo, EMFLAZA® (deflazacort) delays the loss of muscle strength in Duchenne patients and slows the loss of strength over time.1,2

view efficacy
Icon of clinical safety

Understand the clinical safety of EMFLAZA

As with any drug, there is a risk of potential side effects. Learn more about the clinical safety profile of EMFLAZA and how that may impact your patient.1

1. EMFLAZA (deflazacort) [package insert]. South Plainfield, NJ: PTC Therapeutics, Inc. 2. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123-2131.